Profil
David Konciak worked as the Head of Worldwide Immuno Oncology at Bristol Myers Squibb Co. He then worked as the VP of Business Development & Strategic Portfolio at Surface Oncology, Inc. from 2018 to 2020.
Konciak received his undergraduate degree from Muhlenberg College and his MBA from The Wharton School of the University of Pennsylvania.
Anciens postes connus de David Konciak
Sociétés | Poste | Fin |
---|---|---|
SURFACE ONCOLOGY, INC. | Corporate Officer/Principal | 01/01/2020 |
BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
Formation de David Konciak
The Wharton School of the University of Pennsylvania | Masters Business Admin |
Muhlenberg College | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
Entreprise privées | 1 |
---|---|
Surface Oncology, Inc.
Surface Oncology, Inc. BiotechnologyHealth Technology Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company, which engages in the provision of biological pathways critical to the immunosuppressive tumor microenvironment for the development of next-generation cancer therapies. The firm’s pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also includes licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930, Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813, preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA. | Health Technology |